RxDoctor Payments Data

Cheyne Roberts, APRN

Family · Ball Ground, GANPI 1053099168

Payments from drug & device makers

$2,143in general payments, 2019–2025

Across 106 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$556
  • Amgen$300
  • Novo Nordisk$284
  • GSK$204
  • Lilly USA, LLC$172
  • Bayer$122
  • plus $505 from 9 others

What the payments were for

  • Food & beverage$2,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,143 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$35,772
Medicare patients
129
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$35,980
MounjaroTirzepatide27$28,099
FarxigaDapagliflozin Propanediol41$27,934
EliquisApixaban23$23,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,170
RybelsusSemaglutide15$13,982
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,867
Albuterol Sulfate HfaAlbuterol Sulfate37$1,401
Atorvastatin Calcium73$892
Losartan Potassium88$846
Rosuvastatin Calcium60$561
Metformin Hcl ErMetformin Hcl20$546
Metoprolol Succinate17$514
Methylprednisolone57$492
Levothyroxine Sodium42$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$284$49,96253 claims
AstraZenecaFarxiga, Breztri Aerosphere$556$35,80154 claims
Lilly USA, LLCMounjaro$172$28,09927 claims
PfizerEliquis$43$23,51523 claims
GSKTrelegy Ellipta$204$21,17025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Ball Ground

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →